Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy |
| |
| Authors: | N. Oreshkova L. Spel R. P. M. Vloet P. J. Wichgers Schreur R. J. M. Moormann M. Boes J. Kortekaas |
| |
| Affiliation: | aDepartment of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands;bDepartment of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands;cDepartment of Pediatric Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht/Wilhelmina Children''s Hospital, Utrecht, The Netherlands |
| |
| Abstract: | Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+ T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy. |
| |
| Keywords: | |
|
|
